Skip to content
Canada's trusted research peptide sourceFree shipping from $250 CADPurity-tested compoundsPay by Interac e-TransferCanadian owned & operatedFast, discreet shippingCOA-backed qualityCanada-onlyCanada's trusted research peptide sourceFree shipping from $250 CADPurity-tested compoundsPay by Interac e-TransferCanadian owned & operatedFast, discreet shippingCOA-backed qualityCanada-onlyCanada's trusted research peptide sourceFree shipping from $250 CADPurity-tested compoundsPay by Interac e-TransferCanadian owned & operatedFast, discreet shippingCOA-backed qualityCanada-onlyCanada's trusted research peptide sourceFree shipping from $250 CADPurity-tested compoundsPay by Interac e-TransferCanadian owned & operatedFast, discreet shippingCOA-backed qualityCanada-onlyCanada's trusted research peptide sourceFree shipping from $250 CADPurity-tested compoundsPay by Interac e-TransferCanadian owned & operatedFast, discreet shippingCOA-backed qualityCanada-onlyCanada's trusted research peptide sourceFree shipping from $250 CADPurity-tested compoundsPay by Interac e-TransferCanadian owned & operatedFast, discreet shippingCOA-backed qualityCanada-onlyCanada's trusted research peptide sourceFree shipping from $250 CADPurity-tested compoundsPay by Interac e-TransferCanadian owned & operatedFast, discreet shippingCOA-backed qualityCanada-onlyCanada's trusted research peptide sourceFree shipping from $250 CADPurity-tested compoundsPay by Interac e-TransferCanadian owned & operatedFast, discreet shippingCOA-backed qualityCanada-only
Journal

Research news

Retatrutide and sleep apnea.What the TRIUMPH-OSA trials reported.

Two phase 3 sleep apnea trials, now in The New England Journal of Medicine and presented at ObesityWeek 2026, summarized in plain numbers.

By Proof Line Peptides · Published · 4 min read

GLP-3 10 mg labelled research vial

Retatrutide's sleep apnea data reached a peer-reviewed journal this month. The two TRIUMPH-OSA trials were published in The New England Journal of Medicine. The results were presented again at ObesityWeek 2026, held November 14 to 17 in Washington, D.C.

This is a summary of what the investigators and the developer reported. It is not guidance of any kind.

What was studied

Obstructive sleep apnea (OSA) is tracked with the apnea-hypopnea index, or AHI. AHI counts full and partial pauses in breathing per hour of sleep.

The OSA trials were nested "basket" trials inside two larger retatrutide programs. Our earlier post covers the main TRIUMPH obesity results. The knee osteoarthritis baskets were covered in our ACR 2026 summary.

  • TRIUMPH-1-OSA enrolled 243 adults with moderate to severe OSA and obesity or overweight, without type 2 diabetes.
  • TRIUMPH-2-OSA enrolled 448 adults with moderate to severe OSA, obesity or overweight, and type 2 diabetes.
  • Both were phase 3, randomized, double-blind and placebo-controlled.
  • Each had three active study arms and one placebo arm.
  • The primary endpoint was change in AHI at week 80.
  • Mean baseline AHI was 58.6 and 55.9 events per hour.

TRIUMPH-1-OSA: without diabetes

Reported change in AHI at week 80 (hybrid-treatment estimand):

  • Placebo arm: down 9.9 events per hour.
  • Lowest active arm: down 22.9 events per hour.
  • Middle active arm: down 34.3 events per hour.
  • Highest active arm: down 31.7 events per hour.

51.6% of the middle arm and 42.3% of the highest arm finished with mild or no OSA plus low daytime sleepiness scores. The placebo figure was 12.5%. Body weight fell 12.5% to 22.2% across the active arms, versus 4.8% with placebo.

TRIUMPH-2-OSA: with type 2 diabetes

Reported change in AHI at week 80 (hybrid-treatment estimand):

  • Placebo arm: down 10.3 events per hour.
  • Lowest active arm: down 19.2 events per hour.
  • Middle active arm: down 24.7 events per hour.
  • Highest active arm: down 25.4 events per hour.

39.5% of the middle arm and 38.9% of the highest arm reached the same mild-or-no-OSA target, versus 12.6% with placebo. Body weight fell 12.1% to 18.5% across the active arms, versus 5.6% with placebo. HbA1c and fasting glucose also fell more in the active arms.

Why the headline numbers differ

The developer's ObesityWeek announcement cites AHI reductions of up to 36.1 events per hour (60.6%) in TRIUMPH-1. For TRIUMPH-2 it cites up to 28.4 events per hour (48.1%). Those figures are larger than the journal numbers above because they come from a different analysis approach. Trials often report more than one estimand, and each one handles participants who stopped treatment differently. When comparing numbers across articles, check which analysis is being quoted. Our guide to reading a peptide study explains why this matters.

Tolerability

  • Adverse events were reported in 88% to 93% of the active arms in TRIUMPH-1-OSA, versus 76% with placebo.
  • In TRIUMPH-2-OSA the figures were 73% to 84%, versus 71% with placebo.
  • Most events were gastrointestinal and mild to moderate, according to the lead investigator.
  • Serious adverse events were 8% in the active arms and 10% with placebo in both trials.
  • Discontinuation for adverse events: 9 active versus 4 placebo participants in TRIUMPH-1-OSA, and 15 versus 4 in TRIUMPH-2-OSA.
  • One death in a TRIUMPH-2-OSA active arm was attributed to a gastrointestinal cause.

How to read these results

  • The lowest active arm did not reach statistical significance under the testing hierarchy in either trial.
  • Outside experts quoted in coverage said the sleep apnea gains are likely explained by weight loss.
  • One noted there is no evidence yet of a direct effect on breathing control.
  • The lead investigator stressed that participants had both severe sleep apnea and severe obesity.
  • There was no comparison against CPAP. The investigators say a head-to-head study is planned.
  • Eli Lilly funded both trials.

Also at ObesityWeek: staying on treatment

A Cleveland Clinic team presented a target trial emulation built from electronic health records. It looked at adults who started on semaglutide or tirzepatide and then continued, switched or stopped.

  • Switching from semaglutide to tirzepatide was linked to about 3 kg more weight loss at 2 years than continuing semaglutide.
  • Participants who kept any form of obesity treatment, including older agents, maintained weight loss at 2 years.
  • This was observational data, so it shows associations rather than cause and effect.

For background on the comparator, see our semaglutide research guide.

Sources

For laboratory research use only. Not for human or veterinary use.

Shop the vials

Proof Line offers by email.

For laboratory research use only. Not for human or veterinary use.